Global Pulmonary Hypertension Market Size & Forecast to 2019

Pulmonary Hypertension – Global Market Research 2015-2019 is a new research report added by under the Pharmaceutical category. The report considers revenue generated through the sales of various drugs used in the treatment of pulmonary hypertension.

Pulmonary hypertension is a rare disorder that affects the pulmonary arteries carrying deoxygenated blood to the lungs from the heart. The narrowing or blockage of pulmonary arteries will lead to pulmonary hypertension. Symptoms of the disease do not occur until the disease becomes severe. Certain causes of pulmonary hypertension include emphysema, connective tissue disorders, blood clots in lungs, and sleep apnea. Pulmonary hypertension may sometimes lead to several chronic illnesses, such as kidney failure (renal failure), heart failure, aneurysm, heart attack, or, stroke. Endothelin receptor antagonists, prostacyclin analogs, phosphodiesterase inhibitors, and sGC stimulators are popular drug therapeutic classes available for the treatment of pulmonary hypertension.

The analysts forecast global pulmonary hypertension market to grow at a CAGR of 2.92% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global pulmonary hypertension market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of pulmonary hypertension.

The report, Global Pulmonary Hypertension Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.

Key vendors

  • Actelion
  • Bayer
  • GlaxoSmithKline
  • United Therapeutics

Purchase a Copy of the Report @

(Single User License - US $2500)

Other prominent vendors

  • Aires Pharmaceuticals
  • Arena Pharmaceuticals
  • Bial
  • DEKA
  • Dong-A ST
  • Gilead
  • Merck
  • Northern Therapeutics
  • Novartis
  • Pfizer
  • PhaseBio

Key market driver

  • Growing incidence of pulmonary hypertension

Key market challenge

  • Patent expiry

Key market trend

  • Increased focus on combination therapies

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Inquire for this report @

About US: is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.